: NYSE:TDG, NYSE:MOH, NYSE:GDDY, NASDAQ:EDSA, Factors Likely to Have Influenced Earnings Results Navistar International (NYSE:NAV), Earnings and Growth Analysis : NantKwest (NASDAQ:NK), Nothing seems to bother MTS Systems (NASDAQ:MTSC), Aesthetic Medical International Holdings Group, Aluminum Corp. of China Limited ADR Class H Stock Forecast, Analysts Estimate Report : What to Look Out for, Banco Latinoamericano de Comercio Exterior, BrasilAgro - Companhia Brasileira de Propriedades Agrícolas, Canadian Imperial Bank of Commerce Stock Forecast, Centrais Elétricas Brasileiras S.A. - Eletrobrás, China Eastern Airlines Corp. Ltd. ADR Class H, China Eastern Airlines Corp. Ltd. ADR Class H Stock Forecast, China Online Education Group Stock Forecast, China Petroleum & Chemical Stock Forecast, Companhia de Saneamento Básico do Estado de São Paulo - SABESP, Companhia Paranaense de Energia Stock Forecast, Confused? before and after EPS results, Ship Finance International Stock Forecast. Log in to see them here or sign up to get started. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful. In a report issued on October 29, Piper Sandler also maintained a Buy rating on the stock with a $179.00 price target. The company’s shares closed last Thursday at $205.38. All Analyst Report Morningstar • September 02, 2020 Alexion Pharmaceuticals, Inc.: Alexion’s Undervalued Rare-Disease Portfolio Will Withstand Competition; Maintaining $155 FVE He kept his strong buy … Alexion Pharmaceuticals does not currently pay a dividend. There are currently no items in this Watchlist. Alexion Pharmaceuticals, Inc. is expected* to report earnings on 10/29/2020 before market open. 2016 Annual Report. The company’s shares closed last Thursday at $155.92, close to its 52-week high of $162.60. Cookie Notice (). Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) investors will be delighted, with the company turning in some strong numbers with its latest results. Alexion Pharmaceuticals has a P/B Ratio of 2.26. Alexion Pharmaceuticals Inc. analyst ratings, historical stock prices, earnings estimates & actuals. Buy or Sell in volatile market - Analyst report, Corporacion America Airports Stock Forecast, Does Earnings Surprise History Hold Any Clue for, Earnings Report: Here’s what to expect from, Earnings results might Drive Its Stock Price, Empresa Distribuidora y Comercializadora Norte Sociedad Anónima, Expert Strategies Fundamental Traders Can Use To Improve Their Portfolio, Factors Likely to Have Influenced Earnings Results, Fortress Transportation and Infrastructure Investors, Fujian Blue Hat Interactive Entertainment Technology, Guangshen Railway Co. Ltd ADR Class H Stock Forecast, Hancock Jaffe Laboratories Stock Forecast, Hannon Armstrong Sustainable Infrastructure Capital, Hannon Armstrong Sustnbl Infrstr Cap Stock Forecast, Hermitage Offshore Services Stock Forecast, Hewlett Packard Enterprise Stock Forecast, Interpace Diagnostics Group Stock Forecast, InvestcorpCreditManagementBDCInc . Alexion Pharmaceuticals are hiring Business Analyst, France/BeLux in Boston, Massachusetts. Analyst Ratings for Alexion Pharm Inc (ALXN) provide recommendations made by outside industry experts. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Alexion Pharmaceuticals, Inc. Third Quarter 2020 Results. NYSE:CIA, NASDAQ:SLDB, NYSE:SMHI, NASDAQ:ADXS, Earnings and Growth Analysis : NASDAQ:ONCR, NYSE:PAM, NASDAQ:ASPS, NYSE:EXN, Should you short it before the Earnings result? The firm had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.51 billion. It considers technical and fundamental factors and is a good starting point for evaluating a stock. If you are contacted in this manner, please be aware that it is fraudulent, and please do not provide any information or money to these individuals. Oct 29, 2020 at 8:00 AM EDT. Earnings for Alexion Pharmaceuticals are expected to grow by 9.22% in the coming year, from $10.20 to $11.14 per share. Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Alexion Pharmaceuticals (ALXN – Research Report) and Prestige Brand Holdings (PBH – Research Report). The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.27 billion. Alexion Reports Fourth Quarter And Full Year 2020 Results. 2017 Annual Report. An Overall Rank of 77 means that our comprehensive methodology rates Alexion Pharm Inc above 77% of stocks. Intraday data delayed at least 15 minutes or per exchange requirements. Alexion compares favorably to most peers over the near-term (2019-2024) and unfavorably in long-term (2024-2029) revenue growth rates. Alexion Pharmaceuticals does not have a long track record of dividend growth. Alexion@AlexionPharma2 days ago. https://seekingalpha.com/article/4250961-alexion-investor-day-insights According to Zacks Investment Research, based on 10 analysts’ forecasts, the consensus EPS forecast for the quarter is $2.34. Their average twelve-month price target is $141.65, predicting that the stock has a possible upside of 23.33%. Alexion Pharmaceuticals has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. All quotes are in local exchange time. Financial Analyst salaries at Alexion Pharmaceuticals can range from $81,612-$89,356. The reported EPS for the same quarter last year was $2.55. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. In the past three months, Alexion Pharmaceuticals insiders have not sold or bought any company stock. ALXN. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders and cardiology. Alexion is a leading global biopharmaceutical company, with total revenues of almost $5 billion in 2019. MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. See all Financial Analyst salaries to learn how this stacks up … There are currently 7 hold ratings, 14 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of “Buy.”. Alexion Pharmaceuticals, Inc.’s (ALXN Quick Quote ALXN - Free Report) fourth-quarter adjusted earnings of $2.96 per share comfortably beat the Zacks Consensus Estimate of … Historical and current end-of-day data provided by FACTSET. Sector (s) Healthcare. Alexion’s growth has been predominantly dependent on Soliris, as the drug represented 79% of 2019 total net product sales. ALXN updated stock price target summary. Alexion Pharmaceuticals is focused on developing effective drugs for rare diseases. Based on analysts offering 12 month price targets for ALXN in the last 3 months. "Amgen and Alexion's agreement removes "a competitive overhang for Alexion," CFRA analyst Kevin Huang said in a report. He sees Alexion… In a separate report, however, fellow SVB Leerink analyst Geoffrey Porges suggested the $175 per share takeover price might be too low. Intraday Data provided by FACTSET and subject to terms of use. After this action, Bazarko Daniel now owns 30,883 shares of Alexion Pharmaceuticals Inc., valued at $3,795,233 using the latest closing price. Privacy Notice, and Stifel 2020 Virtual Healthcare Conferenc. Listen to Webcast. Subscriber Agreement & Terms of Use, The high price target for ALXN is $165.00 and the low price target for ALXN is $110.00. Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings. Buy or Sell in volatile market – Analyst report Willis Towers Watson Public (NASDAQ:WLTW), Does Earnings Surprise History Hold Any Clue for NASDAQ:LMNR, NASDAQ:FNKO, NASDAQ:INOD, NYSEAMERICAN:TPHS, How Have the Numbers Shaped Up for NYSE:NL, NASDAQ:CMTL, OTCMKTS:GDPMQ, NASDAQ:CHEK, Factors Likely to Have Influenced Earnings Results NYSE:CEPU, NASDAQ:XONE, NYSE:CLPR, NASDAQ:FSTX, Earnings Report: Here’s what to expect from NYSE:RVI, NYSE:RC, NASDAQ:SYBX, NYSE:AIM, , Will stock surge before Earnings results? PEG Ratios around 1 indicate that a company is correctly valued. Alexion is a powerhouse in the market for orphan drugs, a fast-growing pocket of the pharmaceutical industry that focuses on rare diseases. The biopharmaceutical company reported $3.11 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.79. According to analysts’ consensus price target of $141.65, Alexion Pharmaceuticals has a forecasted upside of 23.3% from its current price of $114.85. Alexion Pharmaceuticals has generated $9.74 earnings per share over the last year and currently has a price-to-earnings ratio of 30.7. Alexion Pharmaceuticals last posted its earnings results on July 30th, 2020. Premium. At no time will we ask candidates for fees associated with obtaining software, nor do we provide employees with a cashier’s check to purchase new equipment. Nov 17, 2020 at 10:00 AM EST. View real-time stock prices and stock quotes for a full financial overview. Duke University puts entire undergraduate population into quarantine, California’s Newsom admits pandemic mistakes but says gubernatorial recall push is not justified, Idaho ends Powerball participation amid lawmaker concern that Australia could use lottery revenue for anti-gun measures, ‘No peace’ for markets until 10-year Treasury yield hits 2%, strategist says, Wisconsin Republican Ron Johnson’s remark about feeling safe in Senate during Capitol riot labeled racist, Marco Rubio links his support for unionizing Amazon workers with an accusation of ‘wokeness’ at company, Vaccine-site volunteers frequently rewarded with early shots, What Bond Investors Should Watch This Week: Fed Decision Edition, Nancy Pelosi’s Husband Bought Up This Investment Firm’s Stock, ALXN will report 2021 earnings on 02/03/2022, ALXN will report Q1 2021 earnings on 04/29/2021. Alexion Pharmaceuticals, Inc.: Narrow-Moat Alexion Reports Q4 and Full-Year Results; Modestly Beat Expectations. Today is #EmployeeAppreciationDay and we are deeply grateful for the dedication and resilience of our 3,000+ employees worldwide. 2017 Annual Report. Dec 1, 2020 at 8:50 AM EST. Reports are indicating that there were more than several insider trading activities at ALXN starting from Bazarko Daniel, who sale 24,066 shares at the price of $157.70 back on Dec 17. The report will be for the fiscal Quarter ending Sep 2020. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 . Each plays a critical role in … Alexion Pharmaceuticals has received a consensus rating of Buy. Alexion Pharmaceuticals, Inc. is expected* to report earnings on 10/29/2020 before market open. Directly apply to Alexion Pharmaceuticals and find other jobs near you. 2016 Annual Report. We are using cookies to give you the best experience on our website. The biopharmaceutical company reported $2.96 EPS for the quarter, topping the Zacks' consensus estimate of $2.56 by $0.40. Have Watchlists? Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries. 22 Wall Street analysts have issued ratings and price targets for Alexion Pharmaceuticals in the last 12 months. What this means: Alexion Pharm Inc (ALXN) gets a very positive evaluation from InvestorsObserver's ranking system. If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again. 26.8 MB. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. Alexion Pharmaceuticals last posted its earnings results on July 30th, 2020. The report will be for the fiscal Quarter ending Sep 2020. These are the top analyst upgrades, downgrades and initiations seen on Wednesday, October 7, 2020. : Sinopec Shanghai Petrochemical Stock Forecast, Sociedad Quimica y Minera de Chile Stock Forecast, What Meta Trader4 has to Offer to Forex Traders, Why You Should Plan Your Employees' Benefits Well. According to TipRanks.com, Prasad is a 5-star analyst with an average return of 28.7% and a 62.4% success rate. Will stock surge before Earnings results. Alexion does not contact candidates via instant messaging or chat tools. High institutional ownership can be a signal of strong market trust in this company. For the best MarketWatch.com experience, please update to a modern browser. Visit a quote page and your recently viewed tickers will be displayed here. The company has an excellent track record, having … Does Earnings Surprise History Hold Any Clue for ResMed (NYSE:RMD), Confused? 3rd Annual Evercore ISI HealthCONx Conference. The company’s average rating score is 2.73, and is based on 14 buy ratings, 7 hold ratings, and no sell ratings. The biopharmaceutical company reported $3.11 earnings per share for the quarter, topping analysts’ consensus estimates of $2.32 by $0.79. Alexion Pharmaceuticals has confirmed that its next quarterly earnings report will be published on Thursday, October 29th, 2020. Should you short it before the Earnings result? By using this site you agree to the In a report issued on May 26, Credit Suisse also assigned a Buy rating to the stock with a $142.00 price target. Listen to Webcast. Report Snapshot. FY Report Date: 12/2021: Last Quarter's Earnings: 2.96: Year Ago Earnings: 12.05: Current Quarter's Estimate: 3.18: Current Year's Estimate: 13.12: Median PE on CY Estimate: N/A: Next Fiscal … This browser is no longer supported at MarketWatch. 2015 Annual Report. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). In a report released today, Raju Prasad from William Blair maintained a Hold rating on Alexion Pharmaceuticals. 2015 Annual Report. Create a list of the investments you want to track. Copyright © 2021 MarketWatch, Inc. All rights reserved. Current Price. Something went wrong while loading Watchlist. The reported EPS for the same quarter last year was $2.55. The company had revenue of $1.44 billion for the quarter, compared to analysts’ expectations of $1.27 billion. According to Zacks Investment Research, based on 10 analysts’ forecasts, the consensus EPS forecast for the quarter is $2.34. This estimate is based upon 1 Alexion Pharmaceuticals Financial Analyst salary report(s) provided by employees or estimated based upon statistical methods. Alexion Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $146.89, a 22.7% upside from current levels. Who this matters to: Overall Ranking is a comprehensive evaluation. The P/E ratio of Alexion Pharmaceuticals is 30.71, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.65. Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings results on Wednesday, February 3rd. Only 4.03% of the stock of Alexion Pharmaceuticals is held by insiders. Rating. 2018 Annual Report. Alexion Pharmaceuticals has a PEG Ratio of 1.02. Symbols. The P/E ratio of Alexion Pharmaceuticals is 30.71, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.13. $153.92. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. In the … ALXN - Free Report) is scheduled to release fourth-quarter 2020 results on Feb 4, before market open. 90.12% of the stock of Alexion Pharmaceuticals is held by institutions. Stock Forecast, IRSA Inversiones y Representaciones Sociedad Anónima, Irsa Inversiones y Rprsntcins Stock Forecast, Is it time to Buy before this week’s earning report, Ituran Location and Control Ltd. (US) Stock Forecast, Liberty Tripadvisor Holdings Inc Series A, Loma Negra Compañía Industrial Argentina Sociedad Anónima, Magyar Telekom Távközlési Nyilvánosan Müködö Részvénytársaság, may delivered a positive earnings surprise, Melco Resorts & Entertainment Stock Forecast, Metalla Royalty & Streaming Stock Forecast, Napco Security Technologies Stock Forecast, New England Realty Associates Limited Partnership, New Oriental Education & Technology Group, numbers crunched for you before earnings results, OneSmart International Edun Gr Stock Forecast, Pennsylvania Real Estate Investment Trust, Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk, Reports Strong First-Quarter Financial Results, Schultze Special Purpose Acquisition Stock Forecast, Science Applications International Stock Forecast, Second Sight Medical Products Stock Forecast, Sell or Hold? You can find out more about which cookies we are using or switch them off in settings. Currently, the analyst consensus on Alexion Pharmaceuticals is a Moderate Buy with an average price target of $138.00, which is a 19.6% upside from current levels. 10.7 MB. Cigna (CI) Raymond James analyst John Ransom assigned a Buy rating to Cigna today and set a price target of $250.00. Alexion Provides Update On Phase 3 Study Of Ultomiris® In Hospitalized Patients With Severe Covid-19 . This website uses cookies so that we can provide you with the best user experience possible.
Hc Parfümerie Online, Instagram Ad Rules, Hereditary Persistence Of Fetal Hemoglobin Genetic Testing, Wer Wird Millionär Junior Anleitung, Spielplan 2 Bundesliga Volleyball Herren, Weihnachtsfilme Für Kinder Netflix, Badewannenspielzeug Baby One, Du Kannst Ein Sieger Sein Songwriter, Ramadan Feast 2020, Little Tikes Xylophone Piano Sheet Music, Zeneca Meaning In Latin, Sawsan Chebli Instagram, Tsg Friesenheim Gaststätte Speisekarte,
Schreibe einen Kommentar